Cannabis and Polypharmacy: Prescribing Safely in Complex Patients

Why Polypharmacy Matters in Cannabis Prescribing

• The average UK medical cannabis patient takes 3–5 concurrent medications at the time of initiation
• Cannabis and its constituents are metabolised via CYP450 enzymes, creating interaction potential with many common drugs
• The clinical consequences of cannabis drug interactions range from sub-therapeutic drug levels to serious adverse events
• Polypharmacy review is a mandatory component of the Initial Medical Consultation and all follow-up appointments

Many patients presenting to cannabis clinics in the UK are on complex medication regimens for their underlying conditions. Chronic pain patients may be on opioids, gabapentinoids, SSRIs, and anticoagulants simultaneously. Each of these drug classes has the potential to interact with cannabis constituents, and the prescribing clinician is responsible for identifying and managing these interactions proactively.

Key Drug Interactions: The Evidence

• CBD strongly inhibits CYP2C19: increases plasma levels of clobazam (and its active metabolite norclobazam), clopidogrel, and certain SSRIs
• CBD is a moderate inhibitor of CYP3A4: increases exposure to some statins, certain benzodiazepines, and calcium channel blockers
• THC has CNS depressant effects additive with opioids, benzodiazepines, z-drugs, and alcohol
• Warfarin: multiple case reports document clinically significant INR elevation with CBD — INR monitoring is mandatory if co-prescribed

The interaction between CBD and clobazam is perhaps the best-characterised cannabis drug interaction, having emerged from the GWPHARMA Epidyolex trials. CBD inhibits the CYP2C19-mediated metabolism of clobazam, leading to accumulation of both the parent drug and its active metabolite norclobazam. This interaction can be managed by dose reduction of clobazam, but it requires anticipation and monitoring. Prescribers who are unaware of this interaction risk causing sedation or toxicity in epilepsy patients.

CNS Depressants: The Additive Sedation Risk

• Opioids + high-THC cannabis: additive respiratory depression risk; monitor closely, particularly in COPD patients
• Benzodiazepines + indica-dominant cannabis: profound sedation risk, especially in elderly patients
• Alcohol: cannabis significantly potentiates alcohol intoxication; patients must be counselled explicitly
• Tricyclic antidepressants: potential for additive tachycardia and anticholinergic effects with high-THC preparations

The additive CNS depression from combining cannabis with opioids or benzodiazepines is a real and potentially serious clinical risk. However, it is also one of the most clinically useful interactions: many patients reduce their opioid doses significantly after initiating cannabis, which is a welcome outcome. The key is monitoring — prescribers must track opioid and benzodiazepine doses alongside cannabis dose, watching for signs of excessive sedation or reduced consciousness.

Practical Polypharmacy Management Protocol

• Print or access a full medication list before every prescribing appointment, including OTC medications and supplements
• Use a validated drug interaction checking tool (e.g., Lexicomp, BNF interactions checker) at initiation
• Prioritise monitoring of high-risk interactions: warfarin, clobazam, immunosuppressants (tacrolimus, cyclosporin)
• Communicate interaction risks to the patient’s GP to ensure holistic medicines management across care settings

Polypharmacy management is a team sport. Cannabis prescribers must maintain close communication with the patient’s GP, cardiologist, neurologist, or other relevant specialists to ensure that cannabis initiation triggers appropriate monitoring in those settings. A brief letter to the GP at each prescribing milestone — initiation, dose change, significant adverse event — keeps the primary care team informed and supports joined-up care.